Last reviewed · How we verify

CSII followed by Lina+MET

Sun Yat-sen University · FDA-approved active Small molecule

CSII (continuous subcutaneous insulin infusion) followed by a combination of a DPP-4 inhibitor (linagliptin) and metformin improves glycemic control through sustained insulin delivery and enhanced incretin-based glucose regulation.

CSII (continuous subcutaneous insulin infusion) followed by a combination of a DPP-4 inhibitor (linagliptin) and metformin improves glycemic control through sustained insulin delivery and enhanced incretin-based glucose regulation. Used for Type 2 diabetes mellitus.

At a glance

Generic nameCSII followed by Lina+MET
Also known asCSII+Lina+Met
SponsorSun Yat-sen University
Drug classInsulin therapy combined with DPP-4 inhibitor and biguanide
TargetInsulin receptor (CSII); DPP-4 enzyme (linagliptin); mitochondrial glycerophosphate dehydrogenase (metformin)
ModalitySmall molecule
Therapeutic areaEndocrinology / Diabetes
PhaseFDA-approved

Mechanism of action

CSII provides continuous basal insulin with bolus dosing flexibility to mimic physiologic insulin secretion. Linagliptin inhibits DPP-4, prolonging GLP-1 and GIP activity to stimulate glucose-dependent insulin secretion and suppress glucagon. Metformin reduces hepatic glucose production and improves insulin sensitivity. The sequential approach uses intensive insulin therapy followed by oral agents to optimize glycemic control in type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: